<SEC-DOCUMENT>0001171843-18-004000.txt : 20180516
<SEC-HEADER>0001171843-18-004000.hdr.sgml : 20180516
<ACCEPTANCE-DATETIME>20180516115707
ACCESSION NUMBER:		0001171843-18-004000
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180516
FILED AS OF DATE:		20180516
DATE AS OF CHANGE:		20180516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		18839318

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_051618.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report on Form 6-K dated May 16, 2018</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Commission File No. 1-15024)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>Novartis AG</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name of Registrant)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Lichtstrasse 35</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4056 Basel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of Principal Executive Offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&nbsp;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 8pt"><IMG SRC="logo.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%"><P STYLE="color: #0460A9; font-size: 10pt; font-weight: bold; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Novartis&nbsp;International&nbsp;AG<BR>
                           Novartis&nbsp;Global Communications<BR>
                           <FONT STYLE="font-weight: normal; color: windowtext">CH-4002 Basel</FONT><BR>
                           <FONT STYLE="font-weight: normal; color: windowtext">Switzerland</FONT></FONT></P>

<P STYLE="color: #0460A9; font-size: 10pt; font-weight: bold; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-size: 8pt">http://www.novartis.com</FONT></P>



</TD></TR>
</TABLE>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; background-color: Silver"><FONT STYLE="font-size: 11pt"><B>MEDIA
RELEASE &bull; COMMUNIQUE AUX MEDIAS &bull; MEDIENMITTEILUNG</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-size: 12pt"><B>Novartis announces changes to the Executive Committee</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; font-style: italic; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol; font-style: normal">&middot;</FONT></TD><TD>Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Shannon Thyme Klinger appointed to Group General Counsel</I></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23.75pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Robert Weltevreden appointed Head of Novartis Business Services</I></TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 22.5pt; margin-bottom: 0pt"><B>Basel, May 16, 2018 &ndash;</B> Novartis announced today that Felix R.
Ehrat, Group General Counsel of Novartis, has decided to retire from the company. Shannon Thyme Klinger, currently Chief Ethics,
Risk and Compliance Officer, will be appointed Group General Counsel, effective June 1, 2018.</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">Mr. Ehrat, who has been Group General Counsel and Member of the Executive
Committee of Novartis since 2011, has decided to retire from his position in the context of discussions surrounding Novartis&rsquo;
former agreement with Essential Consultants, owned by Michael Cohen.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">Mr. Ehrat said: &quot;Although the contract was legally in order, it was
an error. As a co-signatory with our former CEO, I take personal responsibility to bring the public debate on this matter to an
end.&quot;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">The Board of Directors and the Executive Committee of Novartis have the
greatest respect for Mr. Ehrat&rsquo;s decision to step down. J&ouml;rg Reinhardt, Chairman of the Board of Directors said: &ldquo;I
appreciate Felix&rsquo;s decision even as we regret his departure. We thank him for his contributions to the company as General
Counsel.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">Vas Narasimhan, CEO of Novartis said: &quot;During his term as Group General
Counsel, Felix was instrumental in further developing the global Legal Department of Novartis, and he played a key role in the
Executive Committee with his proven expertise. Furthermore, he was a dedicated representative of the company&rsquo;s interests
in important national organizations such as economiesuisse, SwissHoldings and Avenir Suisse. The Novartis leadership owes him considerable
thanks for his many contributions and wishes him all the best in his future endeavors.&quot;</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">Shannon Thyme Klinger is currently Chief Ethics, Risk and Compliance Officer.
She became Chief Ethics and Compliance Officer and Global Head of Litigation in 2016 and joined the Novartis Executive Committee
earlier this year. Ms. Klinger joined Novartis in 2011, as General Counsel, North America, Sandoz US. She was then appointed Global
Head Legal and General Counsel for Sandoz. Ms. Klinger holds a JD with Honors from the University of North Carolina at Chapel Hill.
Before joining Novartis, Ms. Klinger was a litigation partner at Mayer Brown LLP and Alston &amp; Bird LLP and was Senior Vice
President and General Counsel for Solvay Pharmaceuticals Inc.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 25.1pt; margin-bottom: 0pt">Vas Narasimhan said: &ldquo;Shannon has
a p<FONT STYLE="color: Black">roven track record as a strong thought leader with a commitment to ethics and integrity. She is
an experienced and gifted lawyer who&rsquo;s already made tremendous contributions to the company. She brings the combination
of private practice and industry experience in Europe and the US that we need, and I have no doubt that the company will benefit
from her judgment and expertise.&rdquo;</FONT></P>



<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 3&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0.2pt 0 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 24pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 24pt; margin-bottom: 0pt"></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Natacha Theytaz, Global Head Internal Audit will lead the Ethics,
Risk and Compliance organization ad interim. Ms. Theytaz will join Novartis from Roche, effective June 1, 2018 as already announced
internally by Novartis in January 2018.</P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">In addition, Novartis announced today that Robert Weltevreden, previously Head
of Business Services for Syngenta will be appointed as Head of Novartis Business Services (NBS). He will report to Vas Narasimhan,
CEO of Novartis and become a member of the Executive Committee of Novartis (ECN). He will join Novartis on June 1, 2018 and will
be based in Basel.</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">At Syngenta, Robert Weltevreden led a business services organization of
a similar scope to NBS; including areas such as finance operations, human resources operations, information technology, real estate
and facility and fleet management, as well as business process, data and project management. Before that he had roles leading Business
Process Management and global Finance Operations for Syngenta. He holds a Masters Degree in International Finance, Economics and
Business Administration from the Erasmus University in Rotterdam and an MBA in Financial Management from the Vlerick School for
Management, Ghent, Belgium.</P>

<P STYLE="font-size: 10pt; margin: 0.05pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&ldquo;Robert&rsquo;s deep understanding of business services coupled with
his strong financial and commercial acumen make him the right person to lead Novartis Business Services (NBS) in the next stage
of its evolution,&rdquo; said Vas Narasimhan. &ldquo;Over the coming years he will play a critical role in driving even higher
levels of productivity and process standardization across Novartis. I am confident that under his leadership our NBS team will
be able to unlock even greater value for us to reinvest in innovation and our exciting product pipeline.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Disclaimer</P>

<P STYLE="margin: 0">This press release contains forward-looking statements within the meaning of the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as <FONT STYLE="font-size: 10pt">&ldquo;will,&rdquo;
&ldquo;appointed,&rdquo; &ldquo;effective,&rdquo; &ldquo;commitment,&rdquo; &ldquo;confident,&rdquo; &ldquo;pipeline,&rdquo; or
similar terms, or by express or implied discussions regarding the potential impact of the announcements regarding Mr. Ehrat and
Ms. Klinger on the reputation of Novartis, and on the Novartis Legal function and on the Ethics, Ris and Compliance function;
regarding the potential impact of the announcement regarding Mr. Weltevreden on the Novartis Business Services organization, including
potential improvements in productivity or business processes, and the potential impact of any such improvements on the Novartis
business, or regarding the potential future financial impact of such changes. You should not place undue reliance on these statements.
Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that as to how these announcements will be received by investors or the public. Nor can there be any
guarantee that Novartis will improve productivity or business processes. Neither can there be any guarantee that any of these
announcements will have any particular impact on the Novartis business. Nor can there be any guarantee that any such changes will
have a positive financial impact on Novartis. In particular, our expectations could be affected by, among other things, the difficulties
inherent in making large-scale change changes to sizeable organizations; the uncertainties inherent in research and development,
including clinical trial results and additional analysis of existing clinical data; unknown potential developments in the Essential
Consultants/Michael Cohen matter and related matters; uncertainties regarding actual or potential legal proceedings, including,
among others actual or potential government investigations; regulatory actions or delays or government regulation generally; our
ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians
and patients; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement
pressures; general economic and industry conditions, including the effects of the persistently weak</FONT>&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 0 18.8pt"></P>



<P STYLE="margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0"></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 24pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 3&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 24pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 24pt; margin-bottom: 0pt"></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="font-size: 10pt; margin-top: 3.7pt; margin-right: 9.25pt; margin-bottom: 0pt">economic and financial environment in many countries; safety, quality
or manufacturing issues, and other risks and factors referred to in Novartis AG&rsquo;s current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any
obligation to update any forward- looking statements contained in this press release as a result of new information, future events
or otherwise.</P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">About Novartis</P>

<P STYLE="font-size: 10pt; margin-top: 0.6pt; margin-right: 5.75pt; margin-bottom: 0pt">Novartis provid<FONT STYLE="color: Black">es
innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals
and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1
billion, while R&amp;D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately
124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more
information, please visit http://www.novartis.com.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.5pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">Novartis is on Twitter.
Sign up to follow @Novartis at http://twitter.com/novartis</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">For Novartis multimedia
content, please visit www.novartis.com/news/media-library</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0.5pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">For questions
about the site or required registration, please contact media.relations@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0 0 0 20.9pt"><FONT STYLE="color: Black"># #</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.35pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">Novartis
Media Relations</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0.6pt; margin-right: 250.65pt; margin-bottom: 0pt"><FONT STYLE="color: Black">Central media
line: +41 61 324 2200</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0.6pt; margin-right: 250.65pt; margin-bottom: 0pt"><FONT STYLE="color: Black">E-mail: media.relations@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: middle">
    <TD STYLE="width: 50%"><FONT STYLE="color: Black">Paul Barrett</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="color: Black">Antonio Ligi</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="color: Black">Novartis Global External Communications</FONT></TD>
    <TD><FONT STYLE="color: Black">Novartis Global External Communications</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="color: Black">+41 61 324 5224 (direct)</FONT></TD>
    <TD><FONT STYLE="color: Black">+41 61 324 1374 (office)</FONT></TD></TR>
<TR STYLE="vertical-align: middle">
    <TD><FONT STYLE="color: Black">+41 79 797 8137 (mobile)</FONT></TD>
    <TD><FONT STYLE="color: Black">+41 79 723 3681 (mobile)&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="color: Black">paul.barrett@novartis.com&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: Black">antonio.ligi@novartis.com&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font-size: 10pt; margin: 0.25pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 3.7pt 0 0 23.75pt"></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">Eric Althoff</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">Novartis Global External Communications</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">+41 61 324 7999 (office)</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">+41 79 593 4202 (mobile) </FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">eric.althoff@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.4pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black"><B>Novartis Investor Relations</B></FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">Central investor relations line: +41 61 324 7944</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"><FONT STYLE="color: Black">E-mail: investor.relations@novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt; color: Black">Central</FONT></TD>
    <TD STYLE="width: 18%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt; color: Black">North America</FONT></TD>
    <TD STYLE="width: 42%"><FONT STYLE="color: Black">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt; color: Black">Samir Shah</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; color: Black">+41 61 324 7944</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Richard Pulik</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 212 830 2448</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Pierre-Michel Bringer</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 1065</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Cory Twining</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 212 830 2417</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas Hungerbuehler</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 8425</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Isabella Zinck</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 7188</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0pt 0"><FONT STYLE="color: Black"><B></B></FONT></P>

<P STYLE="margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 16, 2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL
    PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Group Financial Reporting and
    Accounting</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#F17AI9@  34T *@    @ !0$.  (
M   6   (5@$Q  (    F   (;(=I  0    !   (DIR;  $    L   0LNH<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     &YO=F%R=&ES7VQO9V]?<F=B7W!O<P!!9&]B92!);&QU<W1R871O<B!#
M0R R,#$U("A-86-I;G1O<V@I   !ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      !N &\ =@!A '( = !I ',
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MS_\ $ITHL.C$+)<./?'EK^+5^79S.69Y_0R^'PTVI2_/\K6\V?T9PI2I\/\
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M!GPBWB2[^'/B+Q=X9M[9I]2U31'M3'8 ''[U9)D?&#G<JD>I%>VU\[_M:?\
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M#?0?@UXZU+QQIC3K?Z2@T]9(# X24%FN@GRL0.&/7C->C:=^T2__  OSP/\
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M<T:RQMU5UR#^!HHJ2AP 50J@*HZ 4M%% !1110 4444 %%%% !1110 4444
M%%%% !6;J&CZ1J\(CU;2K/5(QT6[MDE _!@:**:;3NA-)JS':?I6EZ19FWTG
:3;72[<G)BM+=8E_)0!6A110VV[L$DE9'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
